Deferred Tax Assets, Valuation Allowance of Candel Therapeutics, Inc. from 31 Dec 2019 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Candel Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2019 to 31 Dec 2024.
  • Candel Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2024 was $52,185,000, a 29% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Candel Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $52,185,000 +$11,637,000 +29% 31 Dec 2024 10-K 13 Mar 2025 2024 FY
Q4 2023 $40,548,000 +$11,382,000 +39% 31 Dec 2023 10-K 13 Mar 2025 2024 FY
Q4 2022 $29,166,000 +$10,673,000 +58% 31 Dec 2022 10-K 13 Mar 2025 2024 FY
Q1 2022 $29,166,000 31 Mar 2022 10-K 30 Mar 2023 2022 FY
Q4 2021 $18,493,000 +$7,175,000 +63% 31 Dec 2021 10-K 28 Mar 2024 2023 FY
Q4 2020 $11,318,000 +$4,229,000 +60% 31 Dec 2020 10-K 30 Mar 2023 2022 FY
Q4 2019 $7,089,000 31 Dec 2019 10-K 29 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.